 - Results Demonstrate Innate Immune System Activation Through Stimulation of Three Toll-Like Receptors TLRs 2,4,7 - - MIE-101 Therapy Reduced Tumor Growth by 80 Compared to Tumors Treated with Agents Targeting TLRs 2 and 4 or TLR 7 Alone - NOVATO, CA ACCESSWIRE June 29, 2021 Mosaic ImmunoEngineering Inc. Mosaic or the Company, OTCQB:CPMV, a development-stage biotechnology company focused on immunotherapies to treat and prevent cancer and infectious diseases through innate and adaptive immune activation, today announced a new preclinical publication available online in the journal Biomaterials that further expand the understanding of the antitumor potency and mechanism of action of the Companys lead immuno-oncology candidate, MIE-101, cowpea mosaic virus, CPMV a novel Toll-like receptor TLR tri-agonist. Most intratumoral TLR agonists in development engage a single TLR. 